CASC3 and hematologic disorder: Since its FDA approval in 2003 and 2006 for MM and relapsed or refractory MCL (R/R MCL), respectively, BTZ has played a significant role in the treatment of hematologic malignancies, particularly in patients with MM and MCL [78].